Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462106 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
A Phase 1 study of Alzheimers Disease and Prodromal Alzheimer's Disease, sponsored by AC Immune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
- 19
- Study locations
NCT05462106 is a Phase 1 study of Alzheimers Disease and Prodromal Alzheimer's Disease that is actively recruiting participants, run by AC Immune. The registered enrollment target is 176 participants, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (96% lower). The trial reports 19 study locations across 8 states.
The verdict
NCT05462106, a Phase 1 study of Alzheimers Disease and Prodromal Alzheimer's Disease, is actively recruiting participants, sponsored by AC Immune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ACI-24.060 at Dose A
- BIOLOGICAL ACI-24.060 at Dose B
- BIOLOGICAL ACI-24.060 at Dose C
- BIOLOGICAL ACI-24.060 at Dose D
Study Locations (19)
Other
- Fundació ACE, Institut Català de Neurociències Aplicades - Barcelona
- Hospital de la Santa Creu i Sant Pau - Barcelona
- Hospital Universitario Virgen De Las Nieves - Granada
- Hospital Clínico San Carlos - Madrid
- Hospital Universitario de la Princesa - Madrid
- Hospital Universitario Marqués de Valdecilla - Santander
- Hospital Universitario y Politécnico La Fe - Valencia
- Cambridge and Peterborough NHS Foundation Trust - Windsor Research Units - Cambridge
- Liverpool University Hospitals NHS Foundation Trust - Liverpool
- Re:Cognition Health Limited - London
- South London and Maudsley NHS Foundation Trust of The Maudsley Hospital - London
- Oxford Health NHS Foundation Trust - Oxford
Arizona
- Barrow Neurological Institute - Phoenix
Indiana
- Indiana University / IU Health - Indianapolis
Kansas
- University of Kansas Medical Center Research Institute - Fairway
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- The Washington University - St Louis
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- UT Health San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05462106
The ClinicalTrials.gov registry entry for NCT05462106 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (96% lower). The listed sponsor is AC Immune, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Alzheimers Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05462106 reports 19 study locations spanning 8 distinct geographic areas - top geographies include Other, Arizona, Indiana.
Frequently Asked Questions
What is clinical trial NCT05462106 about?
NCT05462106 is a clinical study titled "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)". The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
What is the current status of trial NCT05462106?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2022-06-21. Estimated completion is 2026-06.
What conditions does trial NCT05462106 study?
This clinical trial studies the following conditions: Alzheimers Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, DSAD.
What interventions are being tested in trial NCT05462106?
The interventions under investigation include: Placebo (BIOLOGICAL), ACI-24.060 at Dose A (BIOLOGICAL), ACI-24.060 at Dose B (BIOLOGICAL), ACI-24.060 at Dose C (BIOLOGICAL), ACI-24.060 at Dose D (BIOLOGICAL).
Who is sponsoring clinical trial NCT05462106?
This trial is sponsored by AC Immune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462106 being conducted?
This trial has 19 study locations across Arizona, Indiana, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
-
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.